BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/19/2022 3:18:56 AM | Browse: 775 | Download: 1577
 |
Received |
|
2021-11-11 12:55 |
|
Peer-Review Started |
|
2021-11-11 12:57 |
|
First Decision by Editorial Office Director |
|
2021-12-27 02:50 |
|
Return for Revision |
|
2021-12-27 02:50 |
|
Revised |
|
2021-12-29 11:00 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-03-10 05:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-03-17 04:18 |
|
Articles in Press |
|
2022-03-17 04:18 |
|
Edit the Manuscript by Language Editor |
|
2022-03-08 01:17 |
|
Typeset the Manuscript |
|
2022-04-11 09:31 |
|
Publish the Manuscript Online |
|
2022-04-19 03:18 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Angeliki Bourazana, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis and Andrew Xanthopoulos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andrew Xanthopoulos, FACC, MD, PhD, Doctor, Doctor, Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com |
| Key Words |
Dipeptidyl peptidase-4 inhibitors; Diabetes mellitus; Outcomes; Meta-analysis; Heart failure; Atrial flutter |
| Core Tip |
Dipeptidyl peptidase-4 inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 diabetes mellitus. However, their effect on cardiovascular outcomes in diabetic patients has been neutral. The potential correlation between atrial flutter and dipeptidyl peptidase-4 inhibitors administration is an interesting finding, but since currently there is no sheer underlying pathophysiologic mechanism to justify it, more evidence is required. |
| Publish Date |
2022-04-19 03:18 |
| Citation |
Bourazana A, Giamouzis G, Skoularigis J, Triposkiadis F, Xanthopoulos A. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World J Cardiol 2022; 14(4): 266-270 |
| URL |
https://www.wjgnet.com/1949-8462/full/v14/i4/266.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v14.i4.266 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
